{"id":"W2103524303","doi":"10.1016/s0140-6736(15)61134-5","title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Secukinumab; Medicine; Psoriatic arthritis; Placebo; Internal medicine; Clinical endpoint; Rheumatology; Arthritis; Placebo-controlled study; Gastroenterology; Clinical trial; Immunology; Double blind; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03332117750479653,"score_gpt":0.3242151394148892,"score_spread":0.2908939619100926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}